RecruitingNCT06948487

Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

A Prospective, Multi-center, Observational Study on the Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

Sponsor

Daewoong Pharmaceutical Co. LTD.

Enrollment

12,000 participants

Start Date

Jun 17, 2025

Study Type

OBSERVATIONAL

Conditions

Gastritis

Summary

This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.

Eligibility

Min Age: 19 YearsMax Age: 75 Years

Inclusion Criteria4

Adult subjects between the ages of 19 and 75 years at the time of obtaining written informed consent.
Subjects who are scheduled to receive Fexuclu tablets (fexuprazan) in accordance with the approved indication.
Subjects who present with at least one subjective symptom requiring medical treatment
Subjects who are capable of understanding the information provided, have voluntarily decided to participate in this observational study, and have provided written informed consent for the use of their personal data.

Exclusion Criteria2

Individuals who fall under any contraindications for the administration of Fexuclu tablets (fexuprazan) as specified in the approved labeling.
Individuals who are deemed by the investigator (attending physician) to be inappropriate for participation in this observational study for any reason not otherwise specified.

Interested in this trial?

Get notified about updates and connect with the research team.